<DOC>
	<DOCNO>NCT00813124</DOCNO>
	<brief_summary>The goal clinical research study learn Vidaza ( azacitidine ) give patient CML donor stem cell transplant increase likelihood achieve complete remission CML .</brief_summary>
	<brief_title>Azacitidine After Allo Blood And Marrow Transplantation ( BMT ) Chronic Myelogenous Leukemia ( CML )</brief_title>
	<detailed_description>Study Drug : Azacitidine design block gene cancer cell stop function tumor-fighting gene . By block `` bad '' gene , tumor-fighting gene may able work well . Study Drug Administration Procedures Stem Cell Transplant : If find eligible take part study , give chemotherapy transplant donor cell . The chemotherapy design kill leukemia cell also block body 's ability reject donor cell give transplant . You receive chemotherapy day transplant . You receive transplant Day 0 . This low-level test dose busulfan check fast busulfan process body clear blood . This information help doctor decide dose busulfan receive . You may receive busulfan test dose outpatient week admit hospital inpatient Day -8 ( 8 day stem cell transplant ) . About 11 sample blood ( 1 teaspoon time ) drawn pharmacokinetic ( PK ) test . PK test measure amount study drug body different time point . These blood sample draw various time receive busulfan next 11 hour . These blood draw repeat first day high-dose busulfan treatment ( Day -5 ) . A heparin lock line ( small IV line ) place vein low number needle stick need draws . If possible PK test perform technical scheduling reason , receive standard fix dose busulfan . On Days -5 -2 , receive fludarabine vein 1 hour , busulfan vein 3 hour . If go receive transplant unrelated donor , donor mismatch , also receive antithymocyte globulin ( ATG ) vein 4 hour 3 day transplant . This drug design weaken immune system reduce risk reject transplant . Stem Cell Transplant : After blood-forming cell collect donor , give vein . You give standard drug help decrease risk side effect . You may ask study staff information drug give risk . Drugs Prevent Infections : You receive several drug help stem cell transplant work help decrease risks infection immune system weak . Tacrolimus methotrexate give decrease risk graft-versus-host disease ( GVHD ) , problem may occur donor 's immune cell fight body . - Tacrolimus start 2 day transplant continue long doctor think necessary . This usually 3-12 month , may longer develop GVHD . Tacrolimus give vein non-stop able eat . Once eat , give mouth . - Methotrexate give vein 15-30 minute Days 1 , 3 , 6 , 11 . Several drug also give decrease risk infection . Some antibiotic give vein , give pill . The length time take antibiotic vary . Your doctor describe detail . Study Drug Administration Stem Cell Transplant : You receive azacitidine injection skin day 5 day row , start 5 week transplant . This may repeat month 4 month transplant . You 23 day `` rest '' cycle treatment ( cycle period 28 day ) . If intolerable side effect occur , treatment azacitidine may interrupt stop altogether . Study Visits : You hospital 3-4 week transplant . You check-ups every day leave hospital . After leave , number study visit vary , depend condition . You bone marrow aspiration collect chemotherapy , around 1 , 6 , 12 month transplant . To collect bone marrow aspirate , area hip bone numb anesthetic , small amount bone marrow withdrawn large needle . The bone marrow sample use check status disease learn way azacitidine work . Blood ( 2 teaspoon time ) drawn learn pattern process call methylation . Methylation process body may turn `` '' certain gene . Blood drawn follow time : - At baseline . - Before stem cell transplant ( Day 0 ) . - Six ( 6 ) , 9 , 12 month transplant . - Before receive first dose azacitidine ( Day 1 cycle ) . - After receive last dose azacitidine ( Day 5 cycle ) . Blood ( 8 teaspoon time ) drawn learn body 's immune system recovery , follow time : - Cycle 1- Day 1 - Cycle 1 - Day 14 - Cycle 3 - Day 1 Length Study : You remain study 1 year . You may take study early disease get bad intolerable side effect occur . This investigational study . Azacitidine FDA approve commercially available patient myelodysplastic syndrome . Its use patient CML investigational . All drug use study FDA approve commercially available . Up 57 patient take part study . All enrol MD Anderson .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myelogenous , Chronic , BCR-ABL Positive</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Azacitidine</mesh_term>
	<mesh_term>Busulfan</mesh_term>
	<mesh_term>Antilymphocyte Serum</mesh_term>
	<mesh_term>Vidarabine</mesh_term>
	<criteria>1 . Patients age &lt; = 75 year CML first chronic phase , fail achieve cytogenetic molecular complete remission progress imatinib treatment . Criteria failure international consensus criterion ( Appendix H ) . Patients intolerant tyrosine kinase inhibitor therapy also eligible . 2 . Patients age &lt; = 75 CML accelerate phase blast crisis &lt; = 15 % blast blood bone marrow study entry . 3 . Donor : HLAcompatible related ( HLAA , B , DRB1 match oneantigen mismatch ) HLAcompatible unrelated ( HLAA , B , C DRB1 match oneantigen mismatch ) . 4 . Age 18 75 year . 5 . Zubrod performance status &lt; = 2 . 6 . Left ventricular ejection fraction = &gt; 40 % . 7 . Pulmonary function test within follow parameter : force expiratory volume one second ( FEV1 ) , force vital capacity ( FVC ) diffuse capacity lung carbon monoxide ( DLCO ) = &gt; 50 % expect , correct hemoglobin . 8 . Serum creatinine &lt; 1.5 mg/dL creatinine clearance great equal 40 cc/min . 9 . Serum direct bilirubin &lt; 1.5 mg/dL ( unless Gilbert 's syndrome ) 10 . Serum glutamate pyruvate transaminase ( SGPT ) &lt; = 200 IU/L unless related patient 's malignancy . 11 . Patients treat tyrosine kinase inhibitor , interferon experimental therapy eligible . 12 . Patients age &lt; 75 year CML second subsequent chronic phase . 1 . Uncontrolled infection , respond appropriate antimicrobial agent seven day therapy . 2 . Pleural/pericardial effusion ascites estimate &gt; 1L . 3 . HIVpositive . 4 . Breast feeding pregnancy . Pregnancy mean positive beta human chorionic gonadotropin ( HCG ) test woman child bear potential define postmenopausal 12 month previous surgical sterilization . 5 . Known suspected hypersensitivity azacitidine mannitol . 6 . Patients advance malignant hepatic tumor .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>September 2014</verification_date>
	<keyword>Chronic Myelogenous Leukemia</keyword>
	<keyword>CML</keyword>
	<keyword>Donor stem cell transplant</keyword>
	<keyword>Allogeneic stem cell transplantation</keyword>
	<keyword>Stem cell transplant</keyword>
	<keyword>ATG</keyword>
	<keyword>Antithymocyte globulin</keyword>
	<keyword>Vidaza</keyword>
	<keyword>Azacitidine</keyword>
	<keyword>5-Azacitidine</keyword>
	<keyword>5-Aza</keyword>
	<keyword>5-AZC</keyword>
	<keyword>Ladakamycin</keyword>
	<keyword>NSC-102816</keyword>
	<keyword>allotx</keyword>
	<keyword>Busulfan</keyword>
	<keyword>Busulfex</keyword>
	<keyword>Myleran</keyword>
	<keyword>Fludarabine</keyword>
	<keyword>Fludarabine Phosphate</keyword>
	<keyword>Tacrolimus</keyword>
	<keyword>Methotrexate</keyword>
	<keyword>Azacitidine maintenance therapy</keyword>
	<keyword>molecular remission</keyword>
	<keyword>HLA compatible donor</keyword>
	<keyword>Engraftment</keyword>
	<keyword>Chimerism</keyword>
	<keyword>Graft v host disease</keyword>
	<keyword>GVHD</keyword>
</DOC>